NO944914L - Fremgangsmåte for å inhibere autoimmunsykdommer - Google Patents

Fremgangsmåte for å inhibere autoimmunsykdommer

Info

Publication number
NO944914L
NO944914L NO944914A NO944914A NO944914L NO 944914 L NO944914 L NO 944914L NO 944914 A NO944914 A NO 944914A NO 944914 A NO944914 A NO 944914A NO 944914 L NO944914 L NO 944914L
Authority
NO
Norway
Prior art keywords
autoimmune diseases
inhibiting autoimmune
inhibiting
hexamethyleneamino
och2ch2
Prior art date
Application number
NO944914A
Other languages
English (en)
Other versions
NO944914D0 (no
Inventor
Steven Harold Zuckerman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO944914D0 publication Critical patent/NO944914D0/no
Publication of NO944914L publication Critical patent/NO944914L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Det er beskrevet en fremgangsmåte forlnhiberlng av autoimmunsykdommer som Innbefattende administrering til en menneske som har behov for dette av en effektiv mengde av en forbindelse som har formelen ,OCH2CH2¿ R2 (I) hvor R1 og R3 uavhengig av hverandre er hydrogen, - O O II II -C-(C1-C() alkyl), eller -C-Ar, hvor Ar er eventuelt substituert fenyl; R2 er valgt fra gruppen bestående av pyrrolldin, heksametylenamlno og piperidino; eller et farmasøytisk akseptabelt salt eller solvat derav.
NO944914A 1993-12-21 1994-12-19 Fremgangsmåte for å inhibere autoimmunsykdommer NO944914L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/170,608 US5521198A (en) 1993-12-21 1993-12-21 Methods of inhibiting autoimmune diseases

Publications (2)

Publication Number Publication Date
NO944914D0 NO944914D0 (no) 1994-12-19
NO944914L true NO944914L (no) 1995-06-22

Family

ID=22620579

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944914A NO944914L (no) 1993-12-21 1994-12-19 Fremgangsmåte for å inhibere autoimmunsykdommer

Country Status (15)

Country Link
US (2) US5521198A (no)
EP (1) EP0664123A1 (no)
JP (1) JPH07215855A (no)
KR (1) KR950016723A (no)
CN (1) CN1108102A (no)
AU (1) AU699255B2 (no)
CA (1) CA2138509A1 (no)
CZ (1) CZ320694A3 (no)
HU (1) HUT71327A (no)
IL (1) IL112031A (no)
NO (1) NO944914L (no)
NZ (1) NZ270164A (no)
PH (1) PH31599A (no)
RU (1) RU94044454A (no)
ZA (1) ZA9410083B (no)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US5434166A (en) * 1994-08-22 1995-07-18 Eli Lilly And Company Methods of inhibiting demyelinating and desmyelinating diseases
US5545641A (en) * 1994-10-20 1996-08-13 Eli Lilly And Company Methods of inhibiting physiological conditions associated with an excess of bradykinin
EP0724879A2 (en) * 1995-02-06 1996-08-07 Eli Lilly And Company 2-Phenyl-3-azoylbenzothiopenes for inhibiting effects of IL-6
JPH11510479A (ja) 1995-06-07 1999-09-14 ネオルックス コーポレイション タモキシフェン類似体による心臓血管疾病の予防及び治療
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
US5985932A (en) * 1996-02-28 1999-11-16 Pfizer Inc Inhibition of autoimmune diseases
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US6008232A (en) * 1997-08-20 1999-12-28 Eli Lilly And Company Methods for preventing headaches
IL145470A0 (en) 1999-03-22 2002-06-30 Immugen Pharmaceuticals Inc Compositions for the treatment of immune diseases
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
ES2246234T3 (es) 1999-05-04 2006-02-16 Strakan International Limited Glicosidos de androgenos y actividad androgenica de los mismos.
US6541510B2 (en) * 2000-09-28 2003-04-01 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
US20020137802A1 (en) * 2000-09-28 2002-09-26 Travis Craig R. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
US20030232101A1 (en) * 2002-03-18 2003-12-18 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
JP3887588B2 (ja) * 2002-08-30 2007-02-28 株式会社リガク Ｘ線回折による応力測定法
CA2512021A1 (en) * 2003-01-06 2004-07-29 Wyeth The use of estrogen receptor alpha modulators for the treatment of multiple sclerosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
US5395842A (en) * 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
EP0776661A1 (en) * 1992-10-27 1997-06-04 Nippon Kayaku Kabushiki Kaisha Combined preparation of antiestrogen and glucocorticoid for the treatment of autoimmune disease
JP4111352B2 (ja) 1996-05-21 2008-07-02 新日鐵住金ステンレス株式会社 ステンレス鋼の高清浄化精錬法

Also Published As

Publication number Publication date
US6436958B1 (en) 2002-08-20
AU8153794A (en) 1995-06-29
IL112031A (en) 1999-12-22
JPH07215855A (ja) 1995-08-15
CN1108102A (zh) 1995-09-13
IL112031A0 (en) 1995-03-15
EP0664123A1 (en) 1995-07-26
AU699255B2 (en) 1998-11-26
HUT71327A (en) 1995-11-28
ZA9410083B (en) 1996-06-19
KR950016723A (ko) 1995-07-20
US5521198A (en) 1996-05-28
RU94044454A (ru) 1996-10-10
NO944914D0 (no) 1994-12-19
CZ320694A3 (en) 1995-09-13
CA2138509A1 (en) 1995-06-22
HU9403658D0 (en) 1995-02-28
NZ270164A (en) 1997-08-22
PH31599A (en) 1998-11-03

Similar Documents

Publication Publication Date Title
NO944914L (no) Fremgangsmåte for å inhibere autoimmunsykdommer
NO944919L (no) Fremgangsmåte for å inhibere atrofi av huden eller vagina
NO944928L (no) Fremgangsmåter for inhibering av Alzheimers sykdom
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
NO944927L (no) Fremgangsmåte for inhibering av pulmonar hypertensiv sykdom
MY132056A (en) Methods of inhibiting physiological conditions associated with an excess of neuropeptide y.
DK0652005T3 (da) Fremgangsmåder til inhibering af endometriose
NO944930L (no) Hemming av dysfunksjonell uterin blödning
DK0651999T3 (da) Fremgangsmåder til inhibering af livmoderfibrose
NO944926L (no) Fremgangsmåter for å inhibere myeloperoksidaseaktivitet
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
NO944934L (no) Hemming av vasomotoriske symptomer og tilhörende psykologiske forstyrrelser i forbindelse med post-menopausalt syndrom
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
NO944933L (no) Fremgangsmåte for å inhibere sykdomstilstander i brystet
UA32427C2 (uk) Застосування бензотіофенів або їх фармацевтично прийнятних солей або сольватів для інгібування ангіогенезу і/або ангіогенних захворювань
NO944924L (no) Fremgangsmåter for inhibering av Turner's syndrom
NO944931L (no) Anvendelse av 2-fenyl-3-aroylbenzotiofener for inhibering av tidlig seksuell modenhet
NO975580L (no) Fremgangsmåte for å inhibere melanom
NO973367L (no) Fremgangsmåte for å inhibere miljömessige östrogen
NO981578L (no) FremgangsmÕte for hemming av plasminogenaktivatorhemmer I
NO944909L (no) Fremgangsmåter for inhibering av mannlig infertilitet
NO973609L (no) Fremgangsmåte for å inhibere effektene av IL-6
NO944910L (no) Fremgangsmåte for å inhibere obsessive-kompulsive tilstander og spiseforstyrrelser
NO944577L (no) Hemming av effekten av amyloidogene proteiner
NO944912L (no) Fremgangsmåte for å öke makrofagfunksjonen